US Stock MarketDetailed Quotes

SAB Biotherapeutics (SABS)

Watchlist
  • 3.620
  • -0.100-2.69%
Close May 12 15:59 ET
  • 3.620
  • 0.0000.00%
Pre 04:00 ET
276.80MMarket Cap-6.24P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

SAB Biotherapeutics (SABS) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2026
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
85.64%20M
14.08%48.95M
57.56%15.77M
12.11%12.68M
-4.60%9.73M
-5.43%10.77M
12.70%42.91M
-46.97%10.01M
112.47%11.31M
57.52%10.2M
Selling and administrative expenses
111.89%6.6M
4.43%14.6M
103.97%5.04M
6.62%3.71M
-24.91%2.74M
-25.65%3.11M
-41.25%13.98M
-83.39%2.47M
35.33%3.48M
25.61%3.64M
-General and administrative expense
111.89%6.6M
4.43%14.6M
103.97%5.04M
6.62%3.71M
-24.91%2.74M
-25.65%3.11M
-41.25%13.98M
-83.39%2.47M
35.33%3.48M
25.61%3.64M
Research and development costs
74.97%13.4M
13.56%34.35M
40.21%10.73M
14.55%8.97M
2.56%7M
-6.00%7.66M
83.18%30.25M
78.05%7.65M
94.81%7.83M
86.29%6.82M
Other operating expenses
----
----
----
----
----
----
40.94%-1.32M
62.40%-114.7K
----
-207.70%-263.14K
Operating profit
-85.64%-20M
-14.08%-48.95M
-57.56%-15.77M
-12.11%-12.68M
4.60%-9.73M
5.43%-10.77M
-12.70%-42.91M
46.97%-10.01M
-112.47%-11.31M
-57.52%-10.2M
Net non-operating interest income expense
14,030.27%984.45K
23.13%1.19M
872.97%637.28K
207.29%611.94K
-118.04%-50.78K
-101.68%-7.07K
258.79%967.6K
-83.87%65.5K
459.87%199.14K
701.98%281.44K
Non-operating interest income
1,575.57%1.05M
11.36%1.43M
413.84%700.74K
136.40%655.23K
-96.38%13.56K
-87.45%62.5K
119.84%1.29M
-71.83%136.37K
1,829.64%277.17K
1,211.11%374.56K
Non-operating interest expense
-9.80%62.75K
-24.41%240.66K
-10.46%63.46K
-44.52%43.29K
-30.90%64.35K
-8.91%69.57K
0.99%318.4K
-8.99%70.88K
11.96%78.04K
23.63%93.12K
Other net income (expense)
-97.41%144.4K
678.75%61.04M
-19.05%-1.73M
7,459.30%57.51M
-112.82%-331.43K
-6.07%5.58M
278.61%7.84M
66.93%-1.45M
175.72%760.82K
822.99%2.58M
Gain on sale of security
-109.58%-482.47K
1,065.35%62.75M
-41.06%-3.25M
998,099.77%61.6M
-128.28%-627.06K
-7.91%5.04M
211.65%5.39M
51.21%-2.31M
-96.55%6.17K
720.10%2.22M
Other non- operating income (expenses)
14.68%626.87K
-170.07%-1.72M
78.44%1.53M
-641.50%-4.09M
-19.63%295.63K
15.05%546.63K
463.70%2.45M
153.03%855K
676.52%754.65K
--367.83K
Income before tax
-263.09%-18.87M
138.92%13.27M
-47.97%-16.86M
539.11%45.45M
-37.88%-10.11M
-3.40%-5.2M
19.17%-34.11M
50.15%-11.39M
-102.84%-10.35M
-6.61%-7.34M
Income tax
Net income
-263.09%-18.87M
138.92%13.27M
-47.97%-16.86M
539.11%45.45M
-37.88%-10.11M
-3.40%-5.2M
19.17%-34.11M
50.15%-11.39M
-102.84%-10.35M
-6.61%-7.34M
Net income continuous Operations
-263.09%-18.87M
138.92%13.27M
-47.97%-16.86M
539.11%45.45M
-37.88%-10.11M
-3.40%-5.2M
19.17%-34.11M
50.15%-11.39M
-102.84%-10.35M
-6.61%-7.34M
Minority interest income
Net income attributable to the parent company
-263.09%-18.87M
138.92%13.27M
-47.97%-16.86M
539.11%45.45M
-37.88%-10.11M
-3.40%-5.2M
19.17%-34.11M
50.15%-11.39M
-102.84%-10.35M
-6.61%-7.34M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-263.09%-18.87M
138.92%13.27M
-47.97%-16.86M
539.11%45.45M
-37.88%-10.11M
-3.40%-5.2M
19.17%-34.11M
50.15%-11.39M
-102.84%-10.35M
-6.61%-7.34M
Basic earnings per share
37.50%-0.35
105.98%0.22
71.21%-0.3541
144.64%0.5
-37.97%-1.09
-3.70%-0.56
51.83%-3.68
68.05%-1.23
-15.46%-1.12
41.91%-0.79
Diluted earnings per share
37.50%-0.35
78.53%-0.79
-34.67%-1.6564
81.25%-0.21
-37.97%-1.09
-3.70%-0.56
51.83%-3.68
68.05%-1.23
-15.46%-1.12
41.91%-0.79
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit Opinions
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
(Q1)Mar 31, 2026(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 85.64%20M14.08%48.95M57.56%15.77M12.11%12.68M-4.60%9.73M-5.43%10.77M12.70%42.91M-46.97%10.01M112.47%11.31M57.52%10.2M
Selling and administrative expenses 111.89%6.6M4.43%14.6M103.97%5.04M6.62%3.71M-24.91%2.74M-25.65%3.11M-41.25%13.98M-83.39%2.47M35.33%3.48M25.61%3.64M
-General and administrative expense 111.89%6.6M4.43%14.6M103.97%5.04M6.62%3.71M-24.91%2.74M-25.65%3.11M-41.25%13.98M-83.39%2.47M35.33%3.48M25.61%3.64M
Research and development costs 74.97%13.4M13.56%34.35M40.21%10.73M14.55%8.97M2.56%7M-6.00%7.66M83.18%30.25M78.05%7.65M94.81%7.83M86.29%6.82M
Other operating expenses ------------------------40.94%-1.32M62.40%-114.7K-----207.70%-263.14K
Operating profit -85.64%-20M-14.08%-48.95M-57.56%-15.77M-12.11%-12.68M4.60%-9.73M5.43%-10.77M-12.70%-42.91M46.97%-10.01M-112.47%-11.31M-57.52%-10.2M
Net non-operating interest income expense 14,030.27%984.45K23.13%1.19M872.97%637.28K207.29%611.94K-118.04%-50.78K-101.68%-7.07K258.79%967.6K-83.87%65.5K459.87%199.14K701.98%281.44K
Non-operating interest income 1,575.57%1.05M11.36%1.43M413.84%700.74K136.40%655.23K-96.38%13.56K-87.45%62.5K119.84%1.29M-71.83%136.37K1,829.64%277.17K1,211.11%374.56K
Non-operating interest expense -9.80%62.75K-24.41%240.66K-10.46%63.46K-44.52%43.29K-30.90%64.35K-8.91%69.57K0.99%318.4K-8.99%70.88K11.96%78.04K23.63%93.12K
Other net income (expense) -97.41%144.4K678.75%61.04M-19.05%-1.73M7,459.30%57.51M-112.82%-331.43K-6.07%5.58M278.61%7.84M66.93%-1.45M175.72%760.82K822.99%2.58M
Gain on sale of security -109.58%-482.47K1,065.35%62.75M-41.06%-3.25M998,099.77%61.6M-128.28%-627.06K-7.91%5.04M211.65%5.39M51.21%-2.31M-96.55%6.17K720.10%2.22M
Other non- operating income (expenses) 14.68%626.87K-170.07%-1.72M78.44%1.53M-641.50%-4.09M-19.63%295.63K15.05%546.63K463.70%2.45M153.03%855K676.52%754.65K--367.83K
Income before tax -263.09%-18.87M138.92%13.27M-47.97%-16.86M539.11%45.45M-37.88%-10.11M-3.40%-5.2M19.17%-34.11M50.15%-11.39M-102.84%-10.35M-6.61%-7.34M
Income tax
Net income -263.09%-18.87M138.92%13.27M-47.97%-16.86M539.11%45.45M-37.88%-10.11M-3.40%-5.2M19.17%-34.11M50.15%-11.39M-102.84%-10.35M-6.61%-7.34M
Net income continuous Operations -263.09%-18.87M138.92%13.27M-47.97%-16.86M539.11%45.45M-37.88%-10.11M-3.40%-5.2M19.17%-34.11M50.15%-11.39M-102.84%-10.35M-6.61%-7.34M
Minority interest income
Net income attributable to the parent company -263.09%-18.87M138.92%13.27M-47.97%-16.86M539.11%45.45M-37.88%-10.11M-3.40%-5.2M19.17%-34.11M50.15%-11.39M-102.84%-10.35M-6.61%-7.34M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -263.09%-18.87M138.92%13.27M-47.97%-16.86M539.11%45.45M-37.88%-10.11M-3.40%-5.2M19.17%-34.11M50.15%-11.39M-102.84%-10.35M-6.61%-7.34M
Basic earnings per share 37.50%-0.35105.98%0.2271.21%-0.3541144.64%0.5-37.97%-1.09-3.70%-0.5651.83%-3.6868.05%-1.23-15.46%-1.1241.91%-0.79
Diluted earnings per share 37.50%-0.3578.53%-0.79-34.67%-1.656481.25%-0.21-37.97%-1.09-3.70%-0.5651.83%-3.6868.05%-1.23-15.46%-1.1241.91%-0.79
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Audit Opinions --Unqualified Opinion--------Unqualified Opinion with Explanatory Notes------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +24.74%
Sample Name
Sample Code
 +22.84%
Sample Name
Sample Code
 +19.74%
4
United States Oil Fund LP
USO
+16.51%
5
Powershares Db Multi-Sector Commodi Powershares Db Oil Fund
DBO
+14.47%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +14.63%
Sample Name
Sample Code
 +10.85%
Sample Name
Sample Code
 +6.10%
4
Li Auto
LI
+5.40%
5
Vipshop
VIPS
+3.19%
View More
Middle East conflict spreads to the stock market! How should investors respond?
According to Axios, on Sunday local time, Trump rejected Iran's latest ceasefire proposal, prompting a sharp response from Iran: no one woul Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -